Non Small Cell Lung Cancer News and Research

RSS

Non-Small Cell Lung Cancers are a group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Non-small cell lung cancer is the most common kind of lung cancer.

New summary report highlights advances and challenges in small cell lung cancer research

In 2017, a group of lung cancer experts posed the question: "Can recent advances in tumor biology that have led to progress treating non-small cell lung cancer translate into improved outcomes for small cell lung cancer?"

10 Feb 2020

New therapeutic strategy for lung cancer and associated secondary tumors

In 20 - 40% of patients with cancer, metastasis (the development of secondary tumors) in the central nervous system (CNS) occurs. CNS metastatis impacts negatively on a patient's quality of life, and is associated with a poor health prognosis.

8 Feb 2020

Purdue-developed 'fluorescent markers' begin Phase 3 clinical trials

On Target Laboratories Inc., a privately held biotechnology company developing the use of Purdue University-discovered fluorescent markers to target and illuminate cancer during surgery, has announced the results of a multi-institutional Phase 2 clinical trial in which outcomes were improved for 26% of patients undergoing pulmonary resection for non-small-cell lung cancer.

6 Feb 2020

Analysis shows overall survival in lung cancer patients harboring 'niche' mutations

Mutations were observed in all genes studied, except c-MET, DDR2, MAP2K1, and RET.

5 Feb 2020

Interleukin-1-beta-induced chronic inflammation promotes lung cancer metastasis

The study reveals a detailed epigenetic mechanism for how interleukin-1-beta, a common cytokine that helps fight infections during inflammation, plays a critical role in cancer metastasis.

29 Jan 2020

New technology enhances visualization of lung cancer tissue, helps improve patient outcomes

A groundbreaking tumor-highlighting technology- OTL38- enhances the visualization of lung cancer tissue, providing surgeons with a significantly better chance of finding and removing more cancer than previously possible, according to a scientific presentation at the 56th Annual Meeting of The Society of Thoracic Surgeons.

27 Jan 2020

RB1 alterations in cancer cells may lead to treatment resistance

The Cancer Genetics Group of the Josep Carreras Leukaemia Research Institute, led by Montse Sánchez-Céspedes, together with Luis Montuenga from CIMA, and Enriqueta Felip from Vall d'Hebron Hospital, has revealed that inactivation of RB1 through intragenic rearrangements is frequent in lung cancer cells from non-smoking patients with EGFR mutations.

24 Jan 2020

NUS researchers discover new personalized tool for cancer diagnosis

A team of researchers from the National University of Singapore has discovered a new personalized tool to detect cancer, predict patient survivability and how well a cancer patient would respond to immunotherapy.

14 Jan 2020

Step counters could play role in predicting lung cancer treatment outcomes

Numerous studies have shown that monitoring physical activity promotes better health – from reducing body mass index to watching for signs of hypertension, for example. A new study suggests step counters could play yet another role: predicting outcomes for people undergoing chemoradiation therapy for lung cancer.

8 Jan 2020

High BMI may improve the chance of survival in certain cancers

Above average or high BMI - often linked to cancers, diabetes, cardiovascular and other diseases - may in some cases improve the chance of survival among certain cancers, new research from Flinders University indicates.

26 Dec 2019

Common immune cell linked to failure of checkpoint inhibitors in lung cancer patients

For many lung cancer patients, the best treatment options involve checkpoint inhibitors. These drugs unleash a patient's immune system against their disease and can yield dramatic results, even in advanced cancers.

19 Dec 2019

Study: Chemoradiation regimen for Stage III NSCLC is better than two tested alternatives

Lung cancer is the leading cause of cancer death in the United States and approximately 75-80% of all cases are non-small cell lung cancer (NSCLC).

17 Dec 2019

Novel drug shows efficacy against advanced ROS1 and NTRK fusion-positive NSCLC

Pooled analysis of three phase 1 and 2 clinical trials published online ahead of print in the journal Lancet Oncology show that the drug entrectinib is effective and well-tolerated against advanced ROS1 and NTRK fusion-positive non-small cell lung cancers (NSCLC).

14 Dec 2019

Researchers report substantial county-level variations in surgery rates for early-stage lung cancer

A new study finds more than two-fold differences between counties with the lowest and highest rates of surgery for patients with early stage lung cancer, with socioeconomic and healthcare delivery factors contributing to the gap. The study appears in the journal Chest.

5 Dec 2019

Cleveland Clinic to study ecological, evolutionary mechanisms that contribute to lung cancer

Jacob Scott, M.D., Ph.D., a physician researcher from Cleveland Clinic's Department of Translational Hematology and Oncology Research, recently received a $2.8 million grant from the National Cancer Institute, part of the National Institutes of Health, to study how ecological and evolutionary mechanisms contribute to lung cancer development and progression, and how the interplay between these mechanisms may provide novel treatment insights.

4 Dec 2019

One-third of lung cancer patients have depression symptoms, study finds

About one-third of patients newly diagnosed with the most common form of lung cancer have moderate to severe symptoms of depression, a new study suggests.

4 Dec 2019

Researchers awarded $250,000 grant to study tumor microenvironment in lung cancer

Fueling exploration by investigators who collaborate under a research consortium partnership as recognized by the National Cancer Institute, between Rutgers Cancer Institute of New Jersey and Princeton University, the GO2 Foundation for Lung Cancer has awarded $250,000 toward the identification and development of novel strategies to address treatment resistance in non-small cell lung cancer.

3 Dec 2019

New automated method helps identify cancer cell metabolism inhibitors

UCLA Jonsson Comprehensive Cancer Center researchers have developed a new automated method for testing hundreds of molecules at a time to find out which ones block cancer cells from consuming glucose - the sugars they need to spread and grow.

29 Nov 2019

Secretome of pleural effusions linked to NSCLC and malignant mesothelioma

Cryopreserved cell-free PE fluid from 101 NSCLC patients, 8 mesothelioma and 13 with benign PE was assayed for a panel of 40 cytokines/chemokines using the Luminex system.

25 Nov 2019

Newly developed ChiTaRS database can collect cases of druggable fusion targets

When sections from two separate genes merge due to various factors, such as translocation or splicing, the hybrid that is formed is called a gene fusion. In recent years, it has been discovered that these fusion events play a vital role in the development of cancers and other complex diseases.

20 Nov 2019